奥拉帕尼
PTEN公司
癌症研究
雷达51
浆液性液体
生物标志物
卵巢癌
医学
DNA损伤
DNA复制
聚ADP核糖聚合酶
PARP抑制剂
有丝分裂
生物
癌症
DNA修复
聚合酶
支票1
细胞周期
癌细胞
DNA聚合酶
浆液性卵巢癌
临床试验
细胞周期检查点
肿瘤科
细胞生长
作者
Jie Hao,Bose S. Kochupurakkal,Timothy B. Branigan,Ozge Somuncu,Renyan Liu,Heta Jadhav,Alexandre Andre B.A. da Costa,Yuqing Jiao,Jenny Z. Yu,David B. Martignetti,Golbahar Sadatrezaei,Sirisha Mukkavalli,Prafulla C. Gokhale,Su-Chun Cheng,Steven J. Skates,Dimitrios Nasioudis,Panagiotis A. Konstantinopoulos,Joyce F. Liu,Stephanie L. Gaillard,Robert L. GIUNTOLI
摘要
Ataxia telangiectasia and Rad3-related (ATR) inhibition is under evaluation for the treatment of high-grade serous ovarian cancer (HGSOC) to reverse acquired resistance to poly (ADP-ribose) polymerase (PARP) inhibition and to exacerbate chemotherapy-induced replicative stress. Here, we define PTEN deficiency as a predictive biomarker for the response to ATR inhibition, as monotherapy and in combination with PARP inhibition or gemcitabine. In response to ATR inhibition and compared with PTEN-proficient cells, PTEN-deficient cells are prone to (a) uncoupling of DNA polymerase and helicase activities, leading to excessive ssDNA and replication stress; (b) cytoplasmic sequestration of checkpoint kinase 1 (CHK1), compromising cell-cycle checkpoint control with reduced compensatory effects by ataxia-telangiectasia mutated (ATM) and DNA-dependent proteinase K (DNA-PK), leading to mitotic catastrophe; and (c) reduced DNA repair protein RAD51 homolog 1 (RAD51) recruitment, exacerbating replication fork instability, also leading to lethality. Retrospective analyses revealed that patients with HGSOC who expressed low PTEN levels experienced greater clinical benefit on ATR inhibitor-based trials than did those with high PTEN levels. These results justify prospective trials evaluating ATR inhibition as a therapeutic strategy for PTEN-deficient tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI